H. Heidbuchel, P. Verhamme, M. Alings, M. Antz, W. Hacke et al., European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation, Europace, vol.15, issue.5, pp.625-651, 2013.
DOI : 10.1093/europace/eut083

S. Schulman, A. Kearon, A. Kakkar, P. Mismetti, S. Schellong et al., « Dabigatran versus warfarin in the treatment of acute venous thromboembolism, New England Journal of Medicine, vol.361, issue.24, pp.2345-52, 2009.

M. Patel, K. Mahaffey, J. Garg, G. Pan, D. Singer et al., Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation, Rivaroxaban versus warfarin in non valvular atrial fibrillation, pp.883-91, 2011.
DOI : 10.1056/NEJMoa1009638

URL : https://hal.archives-ouvertes.fr/hal-01038111

A. Kakkar, B. Brenner, and O. Dahl, Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial, The Lancet, vol.372, issue.9632, pp.31-39, 2008.
DOI : 10.1016/S0140-6736(08)60880-6

M. Lassen, W. Ageno, and L. Borris, Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty, New England Journal of Medicine, vol.358, issue.26, pp.2776-2786, 2008.
DOI : 10.1056/NEJMoa076016

P. Lotke, S. Berkowitz, T. Bandel, A. Benson, F. Misselwitz et al., « Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4) : a randomised trial, pp.1673-80, 1016.

D. Rationale, A. Turpie, S. Haas, R. Kreutz, L. Mantovani et al., A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment, doi: 10.2147/VHRM.S30064, pp.363-7094, 2012.

G. Lip, J. Merino, M. Ezekowitz, K. Ellenbogen, D. Zamoryakhin et al., A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study, American Heart Journal, vol.169, issue.5, pp.597-604, 2015.
DOI : 10.1016/j.ahj.2015.02.009

. Selective, Direct Factor Xa Inhibitor, in Humans » , Drug Metabolism et Disposition, pp.2250-2255, 2012.

J. I. Weitz, Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation, Thrombosis and Haemostasis, vol.104, issue.3, pp.633-64, 2010.
DOI : 10.1160/TH10-01-0066

D. Salazar, J. Mendell, H. Kastrissios, M. Green, T. Carrothers et al., Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation, Thrombosis and Haemostasis, vol.107, issue.5, pp.925-961, 2012.
DOI : 10.1160/TH11-08-0566

«. Clemens, Dabigatran etexilate ? a novel, reversible, oral direct thrombin inhibitor : Interpretation of coagulation assays and reversal of anticoagulant activity, Thrombosis and Haemostasis, vol.103, issue.6, pp.1116-1127, 2010.

A. Angelillo-scherrer, « Les anticoagulants oraux directs dans la pratique médicale: implications pour le laboratoire d'hémostase », Pipette -swiss laboratory medicine, pp.17-18, 2014.

O. Pohanka, R. E. Beck, and . Malmström, « On the monitoring of dabigatran treatment in'real life' patients with atrial fibrillation, Thrombosis Research, vol.134, issue.4, pp.783-789, 2014.

G. Freyburger, D. Girard, A. Vervaeke, and M. Rousset, Sylvie Labrouche, « Performance of three functional assays for the measurement of dabigatran plasma concentrations, p.2015

G. Freyburger and D. Girard, « Performance of three functional assays for the measurement of dabigatran plasma concentrations, pp.15-1112

). M. Samama, J. Amiral, C. Guinet, E. Perzborn, and F. Depasse, An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma, Thrombosis and Haemostasis, vol.104, issue.5, pp.1078-1079, 2010.
DOI : 10.1160/TH10-03-0204

M. Samama, Des anciens tests de coagulation ?? ceux plus r??cents, Bio tribune magazine, vol.113, issue.1, 2011.
DOI : 10.1007/s11834-011-0050-z

M. Moisan, G. Freyburger, G. Macouillard, S. Labrouche, and F. Sztark, Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement, Accidents hémorragiques sous anticoagulants oraux (AVK et AOD) aux urgences du CHU de Bordeaux : étude de cohorte rétrospective », thèse du 25 septembre 2015 (74), pp.457-465, 2011.

. Groupe-d-'intérêt-en-hémostase-périopératoire, « Gestion des Anticoagulants Oraux Directs pour la chirurgie et les actes invasifs programmés : propositions réactualisées du Groupe d'Intérêt en Hémostase Périopératoire (GIHP), 2015.

I. Cochois and «. Naco, insertion progressive de la carte de surveillance du patient dans les conditionnements », Le Vidal, rubrique « actualités

B. Kortchinsky, C. M. Vigué, and . Samama, Antagonisation des héparines et des nouveaux anticoagulants », Annales françaises d'anesthésie et de réanimation, pp.37-49, 2013.

R. Marlu, E. Hodaj, and A. Paris, « Effect of noon-specifique reversal agents on anticoagulant activity of dabigatran and rivaroxaban : a randomised crossover ex vivo study in healthy volunteers, Thrombosis Haemostasis, pp.217-224, 2012.

G. Escolar, V. Fernandez-gallego, and E. Arellano-rodrigo, « Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates : signature of studies in vitro with circulation human blood, PloS One, 2013.

X. Wang, S. Mondal, and J. Wang, Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects, American Journal of Cardiovascular Drugs, vol.113, issue.4, pp.147-154, 2014.
DOI : 10.1007/s40256-013-0055-y

S. Glund, V. Moschetti, S. Norris, J. Stangier, M. Schmohl et al., « A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. » Thrombosis Haemostasis, pp.943-51

C. Pollack, P. Reilly, R. Bernstein, R. Dubiel, J. Eikelboom et al., Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran, Thrombosis and Haemostasis, vol.114, issue.1, pp.198-205, 2015.
DOI : 10.1160/TH15-03-0192

A. and L. France, «Protocole d'utilisation thérapeutique et de recueil d'information, ATU de cohorte de l'Idarucizumab, pp.6-2015

G. Lu, F. Deguzman, S. Hollenbach, M. Karbarz, K. Abe et al., A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa, Nature Medicine, vol.48, issue.4, pp.446-51, 2013.
DOI : 10.1038/nm.3102

J. Ansell, S. Bakhru, B. Laulicht, S. Steiner, M. Grosso et al., Use of PER977 to Reverse the Anticoagulant Effect of Edoxaban, Use of PER977 to reverse the anticoagulant effect of edoxaban, pp.2141-2143, 2014.
DOI : 10.1056/NEJMc1411800

K. Senoo, Y. Gregory, and . Lip, « Switching from a vitamin K antagonist to a NOAC », The Lancet haematology, 2015.

A. Das and D. Liu, Novel antidotes for target specific oral anticoagulants, Experimental Hematology & Oncology, vol.371, issue.22, p.2015
DOI : 10.1186/s40164-015-0020-3

J. Schneider, M. Van-eickels, M. Gebel, E. Zell, and A. G. Turpie, « Safety and eff ectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, noninterventional study, Lancet Haematol, vol.3, pp.12-14, 2016.